LOS ANGELES, CA--(Marketwired - February 21, 2017) - ITUS Corporation ("ITUS") (NASDAQ: ITUS), a company using the power of the immune system to diagnose cancer, today announced that its abstract titled "Immuno-Profiling Circulating Blood as a Means of Early Detection of Solid Tumors," has been accepted for a presentation at the national conference of the American Association of Cancer Research ("AACR"), which will be held from April 1 to April 5 in Washington, D.C. Data from ITUS's ongoing cancer patient study will be presented during a poster discussion session.
The discussion will be led by Dr. Amit Kumar, inventor of ITUS's early cancer detection technology. The presentation will be part of a session entitled "Checkpoint Inhibitor and Prognostic Biomarkers," which will take place on April 2, 2017 from 1:00 P.M. to 5:00 P.M, Eastern Time. The abstract will also be published in the Proceedings of the AACR.
Dr. Kumar, Executive Chairman of ITUS Corporation, stated, "We are pleased to have the opportunity to present the latest data from our patient study to a distinguished scientific audience, as AACR attracts leading scientists and physicians at the forefront of cancer research. AACR will mark the first scientific presentation of our data, and as our research and development progresses, we will seek additional opportunities to present our data and publish our results in leading scientific journals."
The AACR (www.aacr.org) is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the cancer field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer. The mission of the American Association for Cancer Research is to prevent and cure cancer through research, education, communication, and collaboration.
ITUS funds, develops, acquires, and licenses emerging technologies in areas such as biotechnology. The Company is developing a platform called Cchek™, a series of non-invasive, blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy. Additional information is available at www.ITUScorp.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
ITUS Corporation: FOCUSED ON INNOVATION™